Alessandro Tavelli

1.6k total citations
55 papers, 372 citations indexed

About

Alessandro Tavelli is a scholar working on Infectious Diseases, Epidemiology and Virology. According to data from OpenAlex, Alessandro Tavelli has authored 55 papers receiving a total of 372 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Infectious Diseases, 21 papers in Epidemiology and 15 papers in Virology. Recurrent topics in Alessandro Tavelli's work include HIV/AIDS drug development and treatment (16 papers), HIV/AIDS Research and Interventions (16 papers) and HIV Research and Treatment (13 papers). Alessandro Tavelli is often cited by papers focused on HIV/AIDS drug development and treatment (16 papers), HIV/AIDS Research and Interventions (16 papers) and HIV Research and Treatment (13 papers). Alessandro Tavelli collaborates with scholars based in Italy, United Kingdom and United States. Alessandro Tavelli's co-authors include Antonella d’Arminio Monforte, Giulia Marchetti, Daniele Tomasoni, Francesca Bai, Diletta Barbanotti, Andrea Antinori, Giovanni Mulè, Debora Mondatore, Camilla Falcinella and Alessandro Cozzi‐Lepri and has published in prestigious journals such as PLoS ONE, Journal of Hepatology and International Journal of Cancer.

In The Last Decade

Alessandro Tavelli

40 papers receiving 368 citations

Peers

Countries citing papers authored by Alessandro Tavelli

Since Specialization

Citations

This map shows the geographic impact of Alessandro Tavelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alessandro Tavelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alessandro Tavelli more than expected).

Fields of papers citing papers by Alessandro Tavelli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alessandro Tavelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alessandro Tavelli. The network helps show where Alessandro Tavelli may publish in the future.

Co-authorship network of co-authors of Alessandro Tavelli

This figure shows the co-authorship network connecting the top 25 collaborators of Alessandro Tavelli. A scholar is included among the top collaborators of Alessandro Tavelli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alessandro Tavelli. Alessandro Tavelli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	ORCHESTRA Delphi consensus: diagnostic and therapeutic management of SARS-CoV-2 infection in solid organ transplant recipients 2025 ·Clinical Microbiology and Infection ·(unknown), Natascia Caroccia, (unknown), Renato Pascale, Effrossyni Gkrania‐Klotsas, Pedro Navarro, Lorenzo Maria Canziani, Alessandro Tavelli, Andrea Antinori, Paolo Grossi, (unknown), Evelina Tacconelli, Zaira R. Palacios‐Baena, Pierluigi Viale, Maddalena Giannella, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	0
2	Safety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with HIV: Insights from the Icona cohort 2025 ·HIV Medicine ·Andrea De Vito, Alessandro Tavelli, Alessandro Cozzi‐Lepri, Andrea Giacomelli, Roberto Rossotti, (unknown), (unknown), (unknown), Antonella Cingolani, Giordano Madeddu, Andrea Antinori, Antonella d’Arminio Monforte	0
3	Long-term immune responses to SARS-CoV-2 Omicron BA.4/5 mRNA booster in people living with HIV 2025 ·Communications Medicine ·Matteo Augello, Valeria Bono, Roberta Rovito, Alessandro Tavelli, Andrea Santoro, Camilla Tincati, Alessandra Vergori, Anna Maria Azzini, Elda Righi, (unknown), Stefano Porru, Silvia Meschi, Stefania Notari, Fabrizio Maggi, Andrea Antinori, Evelina Tacconelli, (unknown), Giulia Marchetti, (unknown)	0
4	All-cause and Cause-specific Mortality in People With HIV in Italy in 1997–2022: Data From the Icona Cohort 2025 ·Open Forum Infectious Diseases ·(unknown), Simone Lanini, Andrea De Vito, (unknown), Maria Mazzitelli, Manuela Ceccarelli, Roberta Gagliardini, Giordano Madeddu, (unknown), Enrico Girardi, (unknown), Giuseppe Lapadula, Carlo Tascini, Alessandro Tavelli, Andrea Antinori, Antonella d'Arminio Monforte	0
5	Effectiveness of dolutegravir-based vs boosted darunavir-based first-line 3-drug regimens in people with HIV with advanced disease: A trial emulation 2025 ·International Journal of Infectious Diseases ·(unknown), Andrea Giacomelli, Cristina Mussini, Stephen R. Cole, Jessie K. Edwards, Carmela Pinnetti, Alessandro Raimondi, Spinello Antinori, Silvia Nozza, Valentina Mazzotta, Giulia Marchetti, Sergio Lo Caputo, Alessandro Tavelli, Antonella d’Arminio Monforte, Andrea Antinori, Alessandro Cozzi‐Lepri	0
6	Do we Still Need Eligibility Criteria to Recommend PrEP? Impact of National Prescribing Requirements on Retention in Care and Sexually Transmitted Infections Acquisition 2024 ·AIDS and Behavior ·Roberto Rossotti, Alessandro Tavelli, (unknown), Anna De Bona, Camilla Muccini, Davide Moschese, (unknown), Alessandro Soria, Simona Bossolasco, Giuseppe Lapadula, Massimo Cernuschi, Antonella d’Arminio Monforte	2
7	OC-10 Effectiveness of long-acting art with cabotegravir/rilpivirine in the icona cohort 2024 ·Roberta Gagliardini, (unknown), Alessandro Tavelli, Giuseppe Lapadula, Valentina Mazzotta, Elena Bruzzesi, (unknown), (unknown), Annalisa Saracino, Stefano Rusconi, Giulia Marchetti, Francesca Ceccherini‐Silberstein, Andrea Antinori, Antonella d’Arminio Monforte, Camilla Muccini	0
8	SARS-CoV-2 mRNA vaccination and short-term changes in viral load and CD4/CD8 T-cell counts in people living with HIV 2024 ·International Journal of Infectious Diseases ·Alessandra Vergori, Alessandro Cozzi‐Lepri, Alessandro Tavelli, Valentina Mazzotta, Anna Maria Azzini, Roberta Gagliardini, Ilaria Mastrorosa, Alessandra Latini, Giovanni Francesco Pellicanò, Lucia Taramasso, Francesca Ceccherini‐Silberstein, Maddalena Giannella, Evelina Tacconelli, Giulia Marchetti, Antonella d’Arminio Monforte, Andrea Antinori	0
9	Persistent poor clinical outcomes of people living with HIV presenting with AIDS and late HIV diagnosis – results from the ICONA cohort in Italy, 2009-2022 2024 ·International Journal of Infectious Diseases ·Annalisa Mondi, Alessandro Cozzi‐Lepri, Alessandro Tavelli, Antonella Cingolani, Andrea Giacomelli, Giancarlo Orofino, Gabriella De Girolamo, Carmela Pinnetti, Andrea Gori, Annalisa Saracino, Alessandra Bandera, Giulia Marchetti, Enrico Girardi, Cristina Mussini, Antonella d’Arminio Monforte, Andrea Antinori	9
10	Tixagevimab/Cilgavimab as SARS-CoV-2 Pre-Exposure Prophylaxis in Lung Transplant Recipients during the Omicron Wave: A Real-World Monocentric Experience 2024 ·Microorganisms ·Andrea Cona, Alessandro Tavelli, (unknown), Neha Hafeez, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Giuseppe Cucinella, Angelo Luca, Alessio Provenzani, Patrizio Vitulo, Alessandro Bertani, Paolo Grossi, Alessandra Mularoni	0
11	Probability of Starting Two-Drug Regimen (2DR) vs. Three-Drug Regimen (3DR) in ART-Naïve and ART-Experienced Person with HIV (PWH) Across the First Wave of COVID-19 Pandemic 2024 ·Viruses ·Alessandra Vergori, Nicola Gianotti, Alessandro Tavelli, Camilla Tincati, Andrea Giacomelli, (unknown), Giuseppe Lapadula, Lucia Taramasso, Loredana Sarmati, Antonella d’Arminio Monforte, Andrea Antinori, Alessandro Cozzi‐Lepri	0
12	Heavily treatment-experienced persons living with HIV currently in care in Italy: characteristics, risk factors, and therapeutic options—the ICONA Foundation cohort study 2024 ·International Journal of Infectious Diseases ·Sergio Lo Caputo, (unknown), Alessandro Tavelli, Roberta Gagliardini, Stefano Rusconi, Giuseppe Lapadula, Andrea Antinori, Daniela Francisci, Loredana Sarmati, Andrea Gori, Vincenzo Spagnuolo, Francesca Ceccherini‐Silberstein, Antonella d’Arminio Monforte, Alessandro Cozzi‐Lepri	2
13	Risk of COVID-19 in-hospital mortality in people living with HIV compared to general population according to age and CD4 strata: data from the ICONA network 2023 ·International Journal of Infectious Diseases ·Andrea Giacomelli, Roberta Gagliardini, Alessandro Tavelli, (unknown), Valentina Mazzotta, Giuliano Rizzardini, Annalisa Mondi, Matteo Augello, Spinello Antinori, Alessandra Vergori, Andrea Gori, Marianna Menozzi, Lucia Taramasso, Francesco Maria Fusco, Andrea De Vito, (unknown), Giulia Marchetti, Antonella d’Arminio Monforte, Andrea Antinori, Alessandro Cozzi‐Lepri	10
14	Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort 2023 ·Liver International ·Antonella d’Arminio Monforte, Alessandro Tavelli, Roberto Rossotti, Roberta Gagliardini, Annalisa Saracino, Sergio Lo Caputo, (unknown), Eugenia Quirós-Roldán, Cristina Mussini, Enrico Girardi, Alessandro Cozzi‐Lepri, Andrea Antinori, Massimo Puoti, (unknown)	1
15	Detection of Asymptomatic Mpox Carriers among High-Ri Men Who Have Sex with Men: A Prospective Analysis 2023 ·Pathogens ·Roberto Rossotti, (unknown), Massimo Cernuschi, Federico D’Amico, Anna De Bona, (unknown), Davide Moschese, Simona Bossolasco, Alessandro Tavelli, Camilla Muccini, Giovanni Mulè, Antonella d’Arminio Monforte	5
16	HIV-Indicator Condition Guided Testing in a Hospital Setting 2023 ·Life ·Diletta Barbanotti, Camilla Tincati, Alessandro Tavelli, Andrea Santoro, (unknown), Teresa Bini, Anna De Bona, Antonella d’Arminio Monforte, Giulia Marchetti	8
17	Correlates of Treatment and Disease Burden in People Living with HIV (PLHIV) in Italy 2022 ·Journal of Clinical Medicine ·Antonella Cingolani, Alessandro Tavelli, Franco Maggiolo, (unknown), Annalisa Saracino, Francesca Vichi, Massimo Cernuschi, Giovanni Guaraldi, Eugenia Quirós-Roldán, Antonella Castagna, Andrea Antinori, Antonella d’Arminio Monforte	2
18	Awareness and perception of accuracy of the Undetectable=Untransmittable message (U=U) in Italy: results from a survey among PLWHA, infectious-diseases physicians and people having unprotected sex 2022 ·AIDS Care ·Antonella Cingolani, Alessandro Tavelli, (unknown), Franco Maggiolo, Enrico Girardi, Alessandro Cozzi‐Lepri, (unknown), (unknown), (unknown), (unknown), (unknown), Roberta Gagliardini, Silvia Nozza, Andrea Antinori, Antonella d’Arminio Monforte, (unknown)	4
19	Real world efficacy of dolutegravir plus lamivudine in people living with HIV with undetectable viral load after previous failures 2022 ·Journal of Global Antimicrobial Resistance ·Roberta Gagliardini, Patrizia Lorenzini, Alessandro Cozzi‐Lepri, Alessandro Tavelli, Vanni Borghi, Laura Galli, G Tagliaferri, Franco Maggiolo, Cristina Mussini, Antonella Castagna, Antonella d’Arminio Monforte, Andrea Antinori	5
20	Improvement of Endurance of DMD Animal Model Using Natural Polyphenols 2015 ·BioMed Research International ·Clementina Sitzia, Andrea Farini, F. Colleoni, Francesco Fortunato, P. Razini, Silvia Erratico, Alessandro Tavelli, (unknown), M. Belicchi, Mirella Meregalli, Giacomo P. Comi, Yvan Torrente	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact